MERS-CoV

• Main Author: Du, Lanying (auth)
• Other Authors: Li, Fang (auth)
• Format: Electronic Book Chapter
• Language: English
• Published: MDPI - Multidisciplinary Digital Publishing Institute 2019
• Subjects: Biology, life sciences; cell-cell fusion; hDPP4; n/a; therapeutics; animal models; HCoV-229E; Drivers; camels; rabbits; SARS-CoV; MERS-CoV; MVA vaccine; transmission; RBD; MERS-CoV nucleocapsid protein; complement; animal model; pseudotyped virus; combination; MERS-coronavirus; peptide; mouse model; spike protein; receptor-binding domain; prevention and treatment; coronaviruses; coronavirus spike glycoprotein; therapeutic antibodies; vaccine platforms; mutation; severe acute respiratory syndrome coronavirus; pathogenesis; fusion inhibitor; Coronavirus; murine CD8+ T cell epitope; lipidomics; authentic virus; correlates of immunity; vaccines; neutralizing monoclonal antibodies; Middle East respiratory syndrome coronavirus; small-molecule inhibitor; Middle East Respiratory Syndrome Virus; DPP4; pyroptosis; cross-neutralization; inflammation; Qatar; spike proteins; One Health; HKU4; nanobodies; mechanism of action; neutralizing antibody; host factors; UHPLC-MS
• Online Access: DOAB: download the publication; DOAB: description of the publication

Summary

Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated from bats; however, different from SARS-CoV, which potentially utilized palm civets as its intermediate hosts, MERS-CoV likely transmits to humans through dromedary camels. Animal models, such as humanized mice and nonhuman primates, have been developed for studying MERS-CoV infection. Currently, there are no vaccines and therapeutics approved for the prevention and treatment of MERS-CoV infection, although a number of them have been developed preclinically or tested clinically. This book covers one editorial and 16 articles (including seven review articles and nine original research papers) written by researchers working in the field of MERS-CoV. It describes the following three main aspects: (1) MERS-CoV epidemiology, transmission, and pathogenesis; (2) current progress on MERS-CoV animal models, vaccines, and therapeutics; and (3) challenges and future prospects for MERS-CoV research. Overall, this book will help researchers in the MERS-CoV field to further advance their work on the virus. It also has important implications for other coronaviruses as well as viruses outside the coronavirus family with pandemic potentials.

Physical Description

1 electronic resource (274 p.)

ISBN

books978-3-03921-851-6
9783039218509
9783039218516

Access

Open Access